3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Completed
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Other
2
Classical hematology
2
Conditions
Multiple Myeloma
4
Mucositis
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, B-Cell
2
Febrile Neutropenia
2
Cytokine Release Syndrome
2
Burkitt Lymphoma
2
Smoldering Multiple Myeloma
1
Recurrence
1
Rectal Neoplasms
1
Polycystic Ovary Syndrome
1
Pancreatic Neoplasms
1
Pancreatic Adenocarcinoma
1
Neurotoxicity Syndromes
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Neoplasm Metastasis
1
Lymphoma, Non-Hodgkin
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Early Stage Triple Negative ER Low Breast Cancer
1
Disease Progression
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Meropenem
5
Ceftazidime
4
Levofloxacin
3
Filgrastim
3
Ciprofloxacin
3
Cefepime
3
Amikacin
3
pegfilgrastim
2
Vancomycin
2
Interleukin 1 Receptor Antagonist Protein
2
Anti-Bacterial Agents
2
Amoxicillin-Potassium Clavulanate Combination
2
pegylated granulocyte colony-stimulating factor
1
Therapeutics
1
Teicoplanin
1
Tazobactam
1
TKN732
1
Surveys and Questionnaires
1
Positron Emission Tomography Computed Tomography
1
Piperacillin
1
Ofloxacin
1
NF protocol
1
Micafungin
1
Metronidazole
1
Magnetic Resonance Myelography
1
Lead
1
Injections
1
Granulocyte Colony-Stimulating Factor
1
Cloxacillin
1
Cilastatin, Imipenem Drug Combination
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
Febrile Neutropenia
×
Interleukin 1 Receptor Antagonist Protein
×
Clear all
NCT03233776
2024-11-18
AFFECT-1
Radboud University Medical Center
Phase 2
Completed
9 enrolled
NCT04099901
2024-11-18
AFFECT-2
Radboud University Medical Center
Phase 2
Completed
88 enrolled